Brazil’s National Health Surveillance Agency Anvisa has confirmed the efficacy of Gelita’s Verisol for skin health, approving its local market use in food supplements.
Collagen supplements in Brazil that deliver a daily dose of 2.5 g of the specific Bioactive Collagen Peptides Verisol from Gelita will be able to use skin health claims under Anvisa’s rules.
The announcement follows the introduction of specific regulations for food supplements in 2018, when manufacturers were called to prove the efficacy of their products. The framework was designed to reduce the information gap in the Brazilian market, especially related to marketing claims that lack scientific proof. The agency is building a positive list of approved ingredients and health claims. Companies have a transition period to adapt existing products.
Gelita’s Dr Stephan Hausmanns, VP, Health & Nutrition commented: “The evaluation process put our product to a high standard test, and we are pleased that the Agency recognised the safety and efficacy of Verisol. This success also demonstrates Gelita’s continuous leadership within the collagen market, emphasising that not all collagen peptides have an equal efficacy. Verisol is so far the only collagen peptide to prove its bioactive benefits for skin health in the Brazilian market”.
Verisol comprises pure collagen peptides designed to provide high efficacy in human skin. They stimulate fibroblast cells in the dermis which substantially increases the renewal and repair of collagen, elastin and proteoglycans – all of which are essential for providing skin elasticity. As a result, the epidermis is supported from within and skin sagging is prevented.
The efficacy of Verisol has been shown to be statistically significant in six different studies specific to the product, involving nearly 500 participants. Its effect on skin elasticity, wrinkles, fine lines, cellulite, nails and hair was researched and confirmed.
